In this context, the signal transducer and activator of transcription 3 (STAT3) signaling pathway has been validated as a promising therapeutic target in metastatic prostate cancer: this protein is aberrantly activated in prostate cancer and contributes to the promotion of metastatic progression [4,5]. This evidence concerns the gene STAT3 and prostate carcinoma.